粒细胞集落刺激因子治疗急性脑梗死的临床研究

目的:探讨粒细胞集落刺激因子(G CSF)治疗急性脑梗死的疗效和安全性。方法:74例急性脑梗死患者随机分为治疗组和对照组。对照组按急性脑梗死常规方法治疗,治疗组在常规治疗基础上加用G CSF。两组病例于治疗前、治疗后1个月和3个月时分别进行Barthel指数(BI)和中国卒中量表(CSS)评定,并观察G CSF治疗期间的不良反应和随访末期的死亡/残障率。结果:71例完成了3个月的观察。治疗组无死亡病例,失访1例;对照组死亡2例。两组治疗后1个月BI和CSS评分即有所改善,但两组差异无显著意义;治疗后3个月,治疗组BI和CSS评分均优于对照组(P<0.01)。治疗组随访末期死亡/残障率为57%,低于对照组的78%(P<0.05)。G CSF治疗期间未出现明显不良反应。结论:G CSF治疗急性脑梗死安全易行,且能改善3个月时的神经功能和预后。

Granulocyte-Colony Stimulating Factor for Acute Cerebral Infarction: A Clinical Study

Objective: To explore the efficacy and safety of granulocyte-colony stimulating factor (G-CSF) in the treatment of acute cerebral infarction. Methods: A total of 74 patients with acute cerebral infarction were randomly divided into 2 groups: the treatment group and the control group. Acute cerebral infarction was treated with routine method in the control group. The treatment group was treated with the above routine method and G-CSF. The two groups were evaluated with Barthel Index (BI) and Chinese Stroke Scale (CSS) prior to the treatment, 1 month and 3 months after treatment. The adverse effects during the G-CSF treatment and the death/disability rate at the end of the follow-up were observed. Results: Seventy-one patients completed the 3-month observation. There was no reported death in the treatment group, and one patient was lost to follow-up. Two patients died in the control group. BI and CSS in both groups improved 1 month after treatment, but there was no significant difference between the two groups. Both BI and CSS in the treatment group were better than those in the control group 3 months after treatment (P<0 01). The death/disability rate of the treatment group was 57% at the end of the follow-up, and it was lower than that of the control group, which was 78% (P<0 05). There was no obvious adverse effect during the G-CSF treatment. Conclusions: The treatment of acute cerebral infarction with G-CSF is both safe and practicable. It may improve nervous function and prognosis at 3 months.